We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Syp3.0
Soy Peptides Research
Mostly mechanism / observationalHigh safety
11 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Soy Peptides studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality randomised trials published 2007–2022 with a typical study size of 31 participants.
Based on 11 studies · 1 RCT · 31 total participants
Confidence
Low
By outcome
Heart & blood pressurePlausible LDL-cholesterol and blood-pressure benefit via LDL-receptor up-regulation and ACE inhibition — but demonstrated mostly in vitro/in animals; the one human lunasin RCT was null · Weeks (uncertain — not established in humans)
Mostly mechanism / observational5 studies
Cholesterol & lipidsPlausible LDL-cholesterol and blood-pressure benefit via LDL-receptor up-regulation and ACE inhibition — but demonstrated mostly in vitro/in animals; the one human lunasin RCT was null · Weeks (uncertain — not established in humans)
Mostly mechanism / observational4 studies
Antioxidant & oxidative stress
Mostly mechanism / observational4 studies
Glucose & metabolicSoy peptides are studied for metabolic/insulin-resistance endpoints, but human glucose data are essentially absent (the lunasin RCT found no glucose change) · Unknown
Too few graded studies1 study
Steady research
3 studies in the last 5 years
200720142022
1RCTn=31 · small study2020
Supplementation with lunasin-enriched soy extract for 8 weeks did not result in significant changes in serum lipids, glucose, insulin resistance, blood pressure, BMI, or waist circumference.
Haddad Tabrizi S, Haddad E, Rajaram S, Oda K, et al. · J Diet Suppl (2020)
Triple-blind, placebo-controlled crossover RCT in 31 adults (mean age 61), 8-week lunasin-enriched soy extract 335 mg/day with a 3-week washout
Nonsignificant reductions across total cholesterol, LDL, triglycerides, fasting glucose, BMI and waist circumference — none reached significance
Authors concluded a higher dose, larger sample, and/or longer treatment are needed to determine any independent lunasin effect
Many soy bioactive peptides... have a variety of physiological functions such as hypolipidemic, anti-hypertensive, and anti-cancer properties... However, more studies are required to further identify their target organs, and elucidate their biological mechanisms of action.
Among these compounds, the peptide lunasin is considered as one of the most promising... against chronic diseases such as cancer, cardiovascular and immunological disorders.
Hsieh CC, Martínez-Villaluenga C, de Lumen BO, Hernández-Ledesma B. · J Sci Food Agric (2018)
Review of lunasin: presence in soybean/derived foods, oral bioavailability, and protective effects
Covers protective/therapeutic effects against cancer, oxidative stress, inflammation, and high cholesterol
Emphasizes mechanisms remain largely preclinical (cell and animal models)
The bioactivity is due to soybean peptides because the ethanol extract of soybean protein which contains isoflavones does not stimulate LDL-R transcription.
Cho SJ, Juillerat MA, Lee CH. · J Agric Food Chem (2007)
Cell-based study: soybean protein hydrolysate (SPH) peptides stimulated LDL-receptor transcription in Hep T9A4 hepatocytes
Effect tracked the peptides (fractions ~200 and 3000 Da), NOT the isoflavone-containing ethanol extract — key distinction from soy isoflavones
Mechanism is up-regulation of LDL-R, not blockage of bile-acid/cholesterol absorption or inhibition of cholesterol synthesis
Lunasin possesses inherent antioxidative, anti-inflammatory, anticancerous properties and could also play a vital role in regulating of cholesterol biosynthesis in the body.
Peptides corresponding to the N-terminal and central regions of lunasin were demonstrated to inhibit angiotensin converting enzyme and to scavenge peroxyl and ABTS radicals.
Indiano-Romacho P, Fernández-Tomé S, Amigo L, Hernández-Ledesma B. · Food Res Int (2019)
Lunasin and its digestion-derived fragments inhibited ACE and scavenged peroxyl/ABTS radicals in vitro
Suggests bioactivity survives (in fragment form) gastrointestinal proteolysis — partially addressing the bioavailability concern
Links the antioxidant and blood-pressure mechanisms to the same peptide family
This peptide... demonstrated to be a potent scavenger of peroxyl and superoxide radicals... preventing of the oxidative damage induced by both chemical agents.
García-Nebot MJ, Recio I, Hernández-Ledesma B. · Food Chem Toxicol (2014)
Lunasin was a potent scavenger of peroxyl and superoxide radicals in vitro
Protected human Caco-2 intestinal cells against H2O2- and tert-butylhydroperoxide-induced oxidative damage
Remained partially intact during cell incubation, supporting intestinal-level activity